Atherosclerotic cardiovascular disease is a chronic condition that often copresents with type
2 diabetes and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are incretin …

Diabetes is a metabolic condition with a rising global prevalence and is characterised by
abnormally high blood glucose levels. Cardiovascular disease (CVD) accounts for the …

Atherosclerotic cardiovascular disease (ASCVD) stands as the leading global cause of
mortality. Addressing this vital and pervasive condition requires a multifaceted approach, in …

Objective To investigate the incidence of cardiovascular disease (CVD) overall and by age,
sex, and socioeconomic status, and its variation over time, in the UK during 2000-19. Design …

An increasing number of individuals are at high risk of type 2 diabetes (T2D) and its
cardiovascular complications, including heart failure (HF), chronic kidney disease (CKD) …

Background: It has been demonstrated that there is a significant reduction in the incidence of
cardiovascular events, mortality rates, and worsening kidney disease in patients using …

The current study evaluated the effect of SGLT-2 inhibitor, dapagliflozin, on left ventricular
remodeling in patients with type 2 diabetes and HFrEF. 60 patients were randomized (1: 1) …

Diabetic cardiomyopathy (DCM), one of the most serious long-term consequences of
diabetes, is closely associated with oxidative stress, inflammation and apoptosis in the heart …

In the primary care setting providers have more tools available than ever before to impact
positively obesity, diabetes, and their complications, such as renal and cardiac diseases. It is …

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been used to reduce glucose
levels in patients with type 2 diabetes mellitus since 2005. This meta-analysis discusses the …